Review Article
The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma
Table 2
Phase III trials of HDT/ASCT in unfavorable NHL patients.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Plus radiotherapy at bulky disease. 2Plus radiotherapy at bulky disease and intrathecal prophylaxis in very high-risk patients. 3Plus intrathecal prophylaxis in very high-risk patients. #See [17, 23, 24]. W.F.: working formulation-NHL classification; Kiel: Kiel classification of NHL; WHO: World Health Organization classification of NHL; CR: complete response; CRu: unconfirmed complete response; PR: partial response; MR: minor response, SD: stable disease, PD: progressive disease; MACOP-B: methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; HDS: high-dose sequential chemotherapy; mito-L-PAM: mitoxantrone and melphalan; VACOP-B: etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; BEAM: carmustine, etoposide, cytarabine, and melphalan; ACBVP: doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; (mega) CEOP: cyclophosphamide, epirubicin, vincristine, and prednisone; ECVBP: epirubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; CHOEP: cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; BEAC: carmustine, etoposide, cytarabine, and cyclophosphamide; HD-CTX: high-dose cyclophosphamide; HD-VP16: high-dose etoposide; N.R.: not reported; N.S.: not significant. |